GlobeNewswire·Jun 8, 2026, 7:00 AM ET

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio announced additional Phase 2 VIBRANT trial data for verekitug in chronic rhinosinusitis with nasal polyps patients will be presented at the EAACI 2026 Congress in Istanbul on June 14, 2026.
The oral session features a responder analysis examining clinically meaningful improvements using efficacy outcome thresholds.
Verekitug is the only known thymic stromal lymphopoietin (TSLP) receptor antagonist currently in clinical development.
Joaquim Mullol, MD, PhD, from Universitat de Barcelona will present the data in Session OAS23 on Sunday, June 14, 2026, from 15:15 to 16:45 TRT in Room Munich.
Verekitug is a recombinant fully human IgG1 monoclonal antibody that binds to the TSLP receptor to inhibit proinflammatory signaling.
TSLP activation initiates downstream targets including IL-4, IL-5, IL-13, IL-17, & IgE, making TSLP receptor blockade a strategy to impact multiple inflammatory processes.
Upstream Bio has advanced verekitug into three Phase 2 trials: the completed positive VIBRANT trial (CRSwNP), the VALIANT trial (severe asthma), & the ongoing VENTURE trial (COPD).
In May 2025, the company initiated the VALOUR trial, a long-term extension study for severe asthma patients who completed the VALIANT trial.